Diabetic neuropathy (DN) remains a leading cause of morbidity in diabetes patients, with an estimated 50% of individuals developing peripheral nerve damage over time. Early detection and accurate risk stratification are critical to preventing irreversible complications such as foot ulcers, amputations, and sensory/motor dysfunction. However, the lack of validated biomarkers and non-invasive diagnostic tools has long hindered clinical management and therapy development. As a preclinical CRO specializing exclusively in diabetes and its complications, Ace Therapeutics is dedicated to bridging this gap. We offer tailored biomarker and diagnostic development services to accelerate the discovery and validation of reliable DN-specific biomarkers and diagnostic solutions for biotech, pharma, and research institutions.

Current Status and Challenges in Diabetic Neuropathy Biomarker and Diagnostic Development

Despite decades of research, DN biomarker and diagnostic development faces persistent hurdles that demand specialized preclinical expertise:

• Low Specificity and Sensitivity: Most existing biomarkers (e.g., metabolic markers, inflammatory cytokines) lack specificity to DN, failing to distinguish it from other neuropathies or diabetes-related comorbidities.
• Late-Stage Detection Limitations: Conventional diagnostic tools (e.g., nerve conduction studies, quantitative sensory testing) often only identify DN once irreversible nerve damage has occurred.
• Translational Gaps: Preclinically identified biomarkers frequently fail to translate to clinical utility due to mismatches between animal models and human DN pathophysiology.
• Complex Pathophysiology: DN involves interconnected mechanisms (oxidative stress, axonal degeneration, metabolic dysfunction) that require multi-dimensional biomarker panels for comprehensive assessment.
• Lack of Standardization: Inconsistent preclinical protocols and sample handling hinder reproducibility and validation of potential biomarkers.

Our Diabetic Neuropathy Biomarker and Diagnostic Assay Development Services

We offer a comprehensive, end-to-end suite of preclinical services tailored to address DN biomarker and diagnostic development needs—from discovery to preclinical validation:

• Biomarker Discovery: Multi-omics-driven screening (lipidomics, metabolomics, transcriptomics, proteomics) of DN models to identify candidate biomarkers linked to nerve damage, inflammation, or repair.
• Biomarker Validation: In vitro (cell-based DN models) and in vivo (rodent DN models) validation of candidate biomarkers, including specificity, sensitivity, and correlation with clinical endpoints (nerve function, histological damage).
• Diagnostic Tool Development: Design and optimization of non-invasive or minimally invasive diagnostic assays (e.g., liquid biopsy-based tests, imaging probes, biosensors) targeting validated DN biomarkers.
• Preclinical Diagnostic Efficacy Testing: Evaluation of diagnostic tools in DN animal models to assess performance metrics (accuracy, precision, early detection capability) and alignment with clinical relevance.
• Biomarker Panel Optimization: Development of multi-biomarker panels to enhance diagnostic specificity and enable risk stratification of DN progression.

Advanced Technology Platforms

Our services are powered by state-of-the-art technology platforms designed to deliver high-quality, translatable data:

• Integrated Multi-Omics Platforms: High-resolution LC-MS/MS (lipidomics/metabolomics), next-generation sequencing (transcriptomics), and multiplex immunoassays (proteomics) for comprehensive biomarker screening.
• Precision DN Animal Models: Phenotypically validated rodent models (streptozotocin-induced, high-fat diet-induced, genetic models) recapitulating human DN pathophysiology for reliable biomarker validation.
• High-Sensitivity Detection Technologies: Single-molecule detection assays, digital PCR, and advanced imaging (confocal microscopy, in vivo imaging systems) for sensitive biomarker quantification and diagnostic tool testing.
• Bioinformatics & Data Analytics Platform: Customized algorithms for biomarker prioritization, pathway analysis, and diagnostic performance modeling (ROC curve analysis, predictive modeling).
• Sample Processing & Quality Control: Standardized workflows for sample preservation, extraction, and QC to ensure reproducibility and data reliability.

Why Partner with Ace Therapeutics?

• Deep Domain Expertise in Diabetes: Our singular focus ensures an unparalleled understanding of diabetic neuropathy pathophysiology, leading to more insightful biomarker study design.
• Integrated, End-to-End Solutions: We manage the entire workflow, from animal model creation and sample collection to omics discovery, assay development, and data analysis, ensuring consistency and accelerating timelines.
• Proven Translational Mindset: We design our preclinical studies with clinical utility as the end goal, focusing on biomarkers that are measurable in accessible human biofluids.

Ace Therapeutics leverages our expertise and advanced platforms to support clients in advancing biomarker discovery and diagnostic development for diabetic neuropathy. Contact Our Biomarker Experts Today to initiate a confidential discussion about your program.

• Diabetic Neuropathy Pathological Research Services
• Diabetic Neuropathy Modeling Services
• Diabetic Neuropathy Drug Development Services

• Mouse Models
• Assay Kits
• Antibodies
• Cell Lines & Lysates
• Proteins & Peptides
• Inhibitors & Activators